US › Healthcare

Qiagen NV (QGEN)

US · Healthcare · Diagnostics & Research

$42.330.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$492.3M
Revenue YoY
+1.8%
Net profit
$68.0M
Profit YoY
-25.0%
EPS
$0.54
EPS estimate
$0.54
Net margin
13.8%

EPS came in at 0.54 against a street estimate of 0.54 — a beat of 0.0%.

Key statistics

Market cap
$8.54B
P/E
21.1
Forward P/E
13.0
P/B
2.56
Book value
$16.15
EPS (TTM)
$1.96
52-week high
$54.44
52-week low
$30.63
50-day MA
$38.66
200-day MA
$43.13
Beta
0.64

Analyst view

Analysts rate Qiagen NV a buy (9 buy, 7 hold, 0 sell out of 16) with an average price target of $44.07.

Shareholding

Insiders
0.47%
Institutions
80.84%

Largest institutional holders

FundStake
Wellington Management Company LLP6.96%
Vanguard Group Inc4.40%
T. Rowe Price Associates, Inc.4.09%
Vanguard Capital Management, LLC2.96%
Deutsche Bank AG2.72%
BlackRock Inc2.55%
Amundi2.31%
Morgan Stanley - Brokerage Accounts2.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Qiagen NV — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.